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Abstract Anti-glycan antibodies represent a vast and yet
insufficiently investigated subpopulation of naturally occur-
ring and adaptive antibodies in humans. Recently, a variety of
glycan-based microarrays emerged, allowing high-throughput
profiling of a large repertoire of antibodies. As there are no
direct approaches for comparison and evaluation of multi-
glycan assays we compared three glycan-based immuno-
assays, namely printed glycan array (PGA), fluorescent
microsphere-based suspension array (SA) and ELISA for
their efficacy and selectivity in profiling anti-glycan anti-
bodies in a cohort of 48 patients with and without ovarian
cancer. The ABO blood group glycan antigens were selected
as well recognized ligands for sensitivity and specificity
assessments. As another ligand we selected P1, a member of
the P blood group system recently identified by PGA as a
potential ovarian cancer biomarker. All three glyco-
immunoassays reflected the known ABO blood groups with
high performance. In contrast, anti-P1 antibody binding
profiles displayed much lower concordance. Whilst anti-P1
antibody levels between benign controls and ovarian cancer
patients were significantly discriminated using PGA (p=
0.004), we got only similar results using SA (p=0.03) but
not for ELISA. Our findings demonstrate that whilst assays
were largely positively correlated, each presents unique
characteristic features and should be validated by an
independent patient cohort rather than another array tech-
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nique. The variety between methods presumably reflects the
differences in glycan presentation and the antigen/antibody
ratio, assay conditions and detection technique. This indicates
that the glycan-antibody interaction of interest has to guide the
assay selection.
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Abbreviations
AUC Area under the curve
Atri (GalNAcα1-3(Fucα1-2)Galβ-) A trisaccharide
BG Blood group
Btri (Galα1-3(Fucα1-2)Galβ-) B trisaccharide
CCC Concordance
correlation coefficient
Glyc-PAA Conjugate of glycan
with poly
[N-(2-hydroxyethyl)
acrylamide]
Glyc-PAA-biot1 End biotin labeled
conjugate of glycan
with poly[N-
(2-hydroxyethyl)
acrylamide]
ELISA Enzyme linked
immunosorbent assay
Glyc Glycan
MFI Median fluorescent
intensity
medTSI Median total signal
intensities
OD Optical density
PBS Phosphate buffered
saline
PGA Printed glycan array
ROC Receiver operating
characteristics
RT Room temperature
SA Suspension array
TACA Tumor associated
carbohydrate antigens
Introduction
Interactions of glycans, namely complex oligosaccharides
attached to a protein or lipid mediate many important
biological processes, such as pathogen recognition [1],
malignant transformation [2], autoimmune disease [3],
neurological disorders [4] and host-versus-graft rejection
[5]. Naturally occurring and adaptive anti-glycan antibodies
are currently the object of both basic research [6, 7] and
biomarker discoveries [8–12].
Ovarian cancer is the sixth most common cause of
cancer-related death of women and the leading cause of
death from gynaecological malignancies [13]. Despite
considerable efforts to improve early detection and advan-
ces in chemotherapy, intra-abdominal metastasis remains a
major challenge in the clinical management of undifferen-
tiated high FIGO (International Federation of Gynecology
and Obstetrics) stage serous ovarian cancers with an overall
five-year survival of 20%. This poor overall prognosis is
due to multiple factors including a lack of early symptoms
and specific screening methods, ineffective therapy for
advanced or recurrent disease, and from limited under-
standing of the early-initiating events and stages of ovarian
cancer development. Therefore, there is an urgent clinical
need for a reliable, non-invasive and affordable serum-
based screening test for ovarian cancers.
In a previous study we used the first custom-made high
throughput printed glycan array (PGA, Cellexicon, San
Diego, USA) and identified specific anti-glycan antibody
patterns in blood of ovarian cancer patients compared to
healthy controls [11]. Whilst it is known that aberrant
glycosylations are found in most cancers, only a limited
number of human antibodies towards tumor associated
carbohydrate antigens (TACA) have been evaluated for
their potential significance in cancer biology. The printed
glycan array [6, 14] consists of a library of over 200
glycans, including well known TACA. Linear modelling
revealed 24 carbohydrate structures for which the amount
of anti-glycan antibodies was significantly lower in the
above mentioned non-mucinous ovarian borderline and
cancer cohort as compared to the healthy patient cohort.
The glycan structure with the most significant discrimina-
tory ability was P1 (Galα1-4Galβ1-4GlcNAcβ; P<0.001),
a member of the P blood group system.
In recent years a number of glycan based microarray
platforms, based on specific (covalent or non-covalent)
immobilization of chemically conjugated glycans on a
modified surface, have been developed for high-throughput
investigations of the glycome [15]. Glycan-based arrays vary
in ligand presentation, glycan origin (isolated from natural
sources or chemically synthesized), assay conditions, detec-
tion method, microspheres (suspension array) and immobili-
zation on flat surfaces (printed glycan array, ELISA); all of
which contribute to the affinity and selectivity of binding [16,
17]. There is a crucial need for standardization and
comparison between various forms of glycan microarrays,
especially taking into account their proven scientific potential
for translational research and subsequent clinical applications.
The increasing number of high-throughput glycan array
studies requires the application of different bioinformatical
analyses for validation and comparison of datasets. However,
to date, only a few reports comparing glycan microarrays and
conventional ELISA have been performed. Most of these
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studies only investigated them in terms of sample size,
dynamic range and sensitivity of measurement (detection
limits) [2, 18–20].
In this present study, which is in line with our previous
development of a glycan-based suspension array, we
compared three glycan-immunoassays for the detection of
the most complicated glycan-binding protein class; anti-
bodies in human plasma. These assays include (1) printed
glycan array; (2) multiplex flow cytometric suspension
assay; and (3) regular direct ELISA, the most established
method. Printed Glycan Array (PGA) as one of the newest
high-throughput microarray technologies [6, 14] allows the
automated detection of an unlimited number of natural and
synthesized glycans in one experimental setting. It is
characterized by high sensitivity and a significant reduction
of reagent consumption. The second approach, multiplex
flow cytometric suspension assay (SA), incorporating
fluorescent microspheres with distinct spectral addresses
as a solid support for ligands, was recently developed for
profiling of anti-glycan antibodies [9, 21]. The advantage of
this assay is reflected by the flexibility and simultaneous
detection of multiple ligands in one sample with minimal
reagent consumption. The third method, conventional direct
ELISA [7, 19, 22, 23], which allows assessment of a
limited number of glycan-protein interactions, is well
established and currently the most widely used method for
this type of application. In both the PGA and ELISA
glycans are positioned onto a flat surface; in PGA glycans
are covalently attached to the surface of a glass slide in a
monovalent form as ω-alkyl glycosides (Glyc-sp-NH2),
whereas in ELISA they are physically adsorbed to
polystyrene in multivalent form, as conjugates with a
polyacrylamide or albumin carrier. In the case of suspension
array (SA), glycans are coupled as end-biotinylated
glycopolymers [24] via streptavidin-biotin reaction to pre-
modified fluorescent beads. All three glycan immunoassays
display various detection specificities resulting in specific
advantages and limitations. ELISA is most relevant for the
investigation of a limited panel of glycans, and would be
suitable for a preliminary survey of new glycan-binding
partners. Printed glycan array allows broad glycan library
screening, and suspension assay has advantages for the
rapid and flexible multiplex detection of up to several
dozen samples. Therefore, all three glycan assays could
be used to study different aspects of glycan-antibody
interactions.
We performed a comparative analysis using three glycan-
based immunoassays for a cohort of 48 patients with and
without ovarian cancer. Two target anti-glycan antibodies were
selected, anti-blood group A/B trisaccharides [6, 25–27] and
our previously identified candidate P1 in order to investigate
the expected anti-glycan antibody distribution in plasma for
each assay.
Material and methods
Clinical cohort
Blood samples were collected prospectively from 48 patients
at the Department of Gynaecology, University Hospital
Zurich, after written informed consent was given (Table 1).
Ethical approval for this study was granted by the appropriate
Ethical Board in 2006 (to V.H.S., SPUK Canton of Zurich,
Switzerland). Two venous blood samples (12 mL) were
collected pre-operatively per patient in EDTA blood tubes
(BD Vacutainer®, 0.184M EDTA, BD Diagnostics, Franklin
Lakes, US) and stored on ice until further processing. Blood
samples were centrifuged at 3000g at 4°C for 10 min, and
aliquots of the supernatant plasma frozen at −80°C. All
collected blood samples were processed using the same
protocol and within 3 h of their collection.
ELISA NUNC MaxiSorp 96-well immunoplates (Thermo
Fisher Scientific, Roskilde, Denmark) were coated with
Glyc-PAA (Lectinity Holdings, Moscow, Russia), 10 μg/
mL, 100 μl per well in carbonate buffer (50 mM Na2CO3/
NaHCO3, pH 9.6) for 12 h at 4°C. Carbohydrate-free PAA
was applied as negative control. Plates were blocked with
1% (w/v) BSA (Sigma-Aldrich Chemie GmbH, Buchs,
Switzerland) in PBS for 40 min at 37°C and washed four
times with PBS containing 0.5% (v/v) Tween-20 after
incubation. Plasma samples were diluted 1:1000 in incuba-
tion buffer (PBS, 0.3% (w/v) BSA, 0.02% (v/v) Tween 20),
added to plates in duplicate and incubated for 60 min at
37°. Between each of the following steps plates were
washed four times with PBS containing 0.5% (v/v) Tween-
20: incubation with 100 μl per well of goat anti-human Ig
(IgA + IgG + IgM) conjugated to long chain biotin for
60 min at 37° (Pierce, Rockford, IL, USA, 0.16 μg/mL in
incubation buffer); streptavidin horse raddish peroxidase
conjugate for 60 min at 37°C (Southern Biotechnology
Associates, Inc., Birmingham, AL, USA, 0.083 μg/mL in
Table 1 Clinicopathological characteristics. Patient numbers and
percentage (in brackets)
Patient cohort (n=48)
Controls 24 (50.0)
Healthy controls 15 (31.3)
Benign tumours 9 (18.7)
Cancers 24 (50.0)
Serous cancer Ovarian 16(31.3)
Peritoneal 5 (10.4)
Tubal 3 (6.3)
FIGO Stage Stage I / II 3 (6.3)
Stage III / IV 20 (41.7)
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incubation buffer); and chromogen substrate 3,3′,5,5′-
tetramethylbenzidine (Sigma-Aldrich Chemie GmbH,
Buchs, Switzerland) for 5 min at RT. The peroxidase
reaction was stopped by addition of equal volumes of 1M
H2SO4. Absorbance was measured at 450 nm using a
TECAN plate reader (Tecan Spectrafluor Plus, Tecan
Trading AG, Männedorf, Switzerland).
Suspension array (SA) The Bio-Plex Suspension Array
(Bio-Rad Laboratories, Hercules, CA, USA) is a multiplex
analysis system that permits the simultaneous analysis of up
to 100 different biomolecules in a single microplate well.
The constituents of each well are drawn up into the flow-
based Bio-Plex array reader, which quantifies each specific
reaction based on its bead color using fluorescently labeled
reporter molecules specific for each target protein followed
by Bio-Plex Manager software data analysis. A 96-well
Multiscreen HTS filter plate (Millipore Corp., Billerica,
MA, USA) was soaked in 100 μl of antibody diluent for
5 min (PBS-0.05 M Tris, pH 7.2, 0.25% BSA, Sigma-
Aldrich Chemie GmbH, Buchs, Switzerland). Antibody
diluent incorporating 2000 beads/well (50 μl/well) was
added. The plate was washed three times with 100 μl of
washing buffer (PBS-0.05 M Tris, pH 7.2) using a vacuum
manifold (Bio-Rad, Munich, Germany). Human samples
were added in duplicates to wells (in antibody diluent 1:40
(50 μl/well)) and agitated at 1,100 rpm for 30 s on a
microplate shaker before incubation on a shaker (200–
300 rpm) for 1 h at RT in the dark. After incubation, the
plate was washed three times using washing buffer.
Secondary antibodies (R-phycoerythrin conjugated goat
anti-human Ig (IgM + IgG + IgA, H + L; Southern
Biotechnology Associates Inc., Birmingham, AL, USA,
25 ng/well) were added and incubated for 30 min on the
plate shaker in the dark. The plate was washed three times
with washing buffer, beads were then resuspended and
shaken for 30 s at 1,100 rpm in 100 μl of washing buffer
before being analyzed on the Bio-Plex array reader. Data were
acquired in real time analyzing 100 beads by their median
fluorescence intensitiy (MFI) using a computer software
package (Bio-Plex Manager 4.1; Bio-Rad Laboratories,
Hercules, CA, USA).
Coupling procedure The end-biotinylated glycopolymers for
coupling to fluorescent microspheres, Glyc-PAA-biot1, were
produced in-house (Laboratory of Carbohydrates,
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry,
Russian Academy of Sciences, Moscow, Russian Federation).
Biotinylated glycopolymers were coupled to fluorescent
carboxylated beads of 5.5 μm diameter with distinct spectral
“addresses” (Bio-Rad Laboratories Inc., Hercules, CA, USA).
Each set of beads was embedded with a precise ratio of red
and infrared fluorescent dyes allowing its identification by
measuring the intensities of the two classifier fluorochromes.
The stock vial of microspheres (1.25×107 microspheres/mL)
was vortexed for 30 s and sonicated for 30 s in a water bath
prior its use. Bead suspension (100 μl; 1.25×106 micro-
spheres, 0.2 nmol –COOH groups in total, according to the
supplier’s information) was centrifuged for 4 min, 14,000 g at
RT. The pellet was resuspended in bead wash buffer (100 μl;
Bio-Plex amine coupling kit, Bio-Rad Laboratories Inc.,
Hercules, CA, USA) by vortexing and sonication, and
washed by centrifugation as described above. After gentle
removal of supernatant, the pellet was resuspended in 80 μl
of bead activation buffer (Bio-Plex amine coupling kit, Bio-
Rad Laboratories Inc., Hercules, CA, USA), vortexed and
sonicated. Sulfo-N-hydroxysuccinimide sodium salt (S-NHS)
and 1-ethyl-3-[3,3-dimethylaminopropyl]carbodiimide hydro-
chloride (EDC; Pierce Biotechnology, Rockford, IL, USA,
both 50 mg/mL in activation buffer) were prepared immedi-
ately prior to use, and 10 μl of each solution was added to the
bead suspension, followed by vortexing for 30 s. Beads were
incubated on a vertical rotor in the dark for 20 min at RT. The
activated beads were centrifuged and supernatant removed.
The pellet was resuspended in 150 μl biotin-solution (0.1 M
NaHCO3, pH 8.3, containing 1 μg (≈ 2 nmol) of biotin-NH
(CH2)6NH2. Lectinity Holdings, Moscow, Russia) and incu-
bated on a vertical rotor with medium speed for 2 h at RT in
the dark. Obtained biotinylated beads were pelleted by
centrifugation and resuspended in 150 μl of 50 mM
ethanolamine (Sigma-Aldrich Chemie GmbH, Buchs, Swit-
zerland) in 0.1 M NaHCO3, pH 9.0 to quench unbound
activated groups. Beads, protected from light, were agitated
on a rotator for 30 min at RT and centrifuged. The pellet was
washed twice with 500 μl PBS, pH 7.4 and resuspended in
streptavidin-solution (400 pmol streptavidin in 150 μl PBS;
Bio-Rad Laboratories Inc., Hercules, CA, USA). Suspended
bead were vortexed and agitated on a rotator in the dark for
2 h at RT or 12 h at 4°C. Beads were washed twice with
500 μl PBS followed by centrifugation. Glyc-PAA-biot1
solutions in water (20 pmol end-biotin labeled Glyc-PAA,
∼30 kDa, Glyc contents - 20% mol) [24], were added with
1.25×106 streptavidin-coated beads in 150 μl PBS to the
reaction tubes. The mixture was protected from light and
agitated on a rotator for 6 h at RT. Modified microspheres
were centrifuged, supernatant removed and beads washed
twice with 500 μl of bead storage buffer (Bio-Rad
Laboratories Inc., Hercules, CA, USA). Beads were
centrifuged and resuspended in 100 μl of bead storage
buffer and concentration determined using a hemocytometer
(Roth AG, Karlsruhe, Germany) before storing at 4°C,
protected from light.
Printed glycan array (PGA) Printed glycan array slide
fabrication and high-throughput profiling was performed as
previously described [6, 11, 14]. Briefly, monomeric
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glycans as ω-aminopropyl glycosides of 95–98% purity
(Lectinity Holdings, Moscow, Russia) were diluted in
300 mM phosphate buffer pH 8.5, containing 0.005%
Tween 20 and printed by robotic pin deposition on N-
hydroxysuccinimide activated glass slides (Nexterion Slide
H, Schott, Jena, Germany). Glycans were printed at a
50 μM concentration in eight replicates. Free N-hydrox-
ysuccinimide activated groups were blocked with 50 mM
ethanolamine in 50 mM borate buffer at a final pH of 9.2.
Slides were then rinsed with deionized water, dried and
stored at room temperature in a desiccator. Each plasma
sample was diluted 1:15 with PBS containing 0.1% v/v
Tween20 and 3% w/v BSA, thoroughly vortexed for 15 s
and incubated at 37°C for 15 min to dissolve potential lipid
aggregates. Samples were transferred to the array slides and
gently rocked in a sealed humidified incubator for 2 h at
37°C. Unbound sample components were washed with a
series of 0.1% and 0.001% Tween-20 in PBS. Antibody
solution and goat anti-human IgA + IgG + IgM conjugated
to long chain biotin (Pierce Biotechnology, Rockford, IL,
USA, 1:100 (20 μg/mL) in PBS containing 0.1% Tween-20
and 3% BSA) was added. Slides were incubated at RT in a
humidified chamber for 45 min and then washed. Bound
antibodies were visualized by incubating slides with
fluorescent dye streptavidin solution (Alexa Fluor555,
Molecular Probes, Invitrogen, Carlsbad, CA, USA, 1:1000
in PBS/0.1% Tween-20) at RT for 30 min. Fluorescence
signals corresponding to glycan-bound antibodies were
measured and quantified using ImaGene analysis software
version 6.1 and 7.5 (BioDiscovery, El Segundo, USA).
Signals were measured as total signal intensity (medTSI)
per glycan and were expressed as median across eight intra-
array replicates. In a prior discovery approach we screened
plasma of non-mucinous ovarian cancer patients in com-
parison to healthy controls and revealed anti-P1 antibodies
to be the most specific differentiating anti-glycan antibody.
Apart from the standard ABO blood group system we have
therefore used anti-P1 in this comparative analysis as an
example of a new biomarker identified by PGA only.
Controls and validation procedures
Due to the known high expression levels in healthy controls
α-rhamnose was used as a “positive biological control” in
the PGA experiments [10]. Aminoglucitol, an opened
reduced form of D-glucose which is not present as a
structural component of regular glycosylation, has shown to
be negative for anti-glycan binding at similar values to the
technical background [6, 11]. We therefore used it as a
negative biological control in both PGA and SA experi-
ments, where MFI signals for aminoglucitol binding did not
exceed 200 and were close to the technical cut-off in all
individual samples (data not shown). A glycan-free poly-
mer (PAA) was used in ELISA as a control for non-specific
binding and displayed lower signals than the lowest signals
for Glyc-PAA coating in all cases (data not shown). Human
polyclonal antibodies against A/B blood group antigens
were used to test the coupling effectiveness in SA. Anti-
glycan antibodies were purified from pooled human plasma
of the same blood group using affinity chromatography as
previously described [7, 21]. Polyclonal anti-glycan anti-
bodies bound to cognate glycans in a dose-dependent
manner displayed no or very low cross-reactivity to other
glycans in both SA and ELISA (data not shown).
Anti-A/B antibody screening
Thewell knownABO blood group carbohydrate antigenswere
used as a model for the comparison of our three glycan
immunoassays. ABO-specific antibodies (isohaemagglutinins)
belong to a group of naturally occurring antibodies [28] which
can be detected by the haemagglutination test, ELISA [22,
23] and flow cytometry [29]. Blood group information was
available for 31 patients, of whom 13 patients had blood
group A (41.9%), 6 patients blood group B (19.3%), 2
patients blood group AB (6.4%) and 10 patients blood group
O (32.2%). Antibody profiles for Atri (GalNAcα1-3 (Fucα1-
2)Galβ) and Btri (Galα1-3(Fucα1-2)Galβ) blood group
antigens were generated using SA, ELISA and PGA. Raw
data were acquired for all technologies in different units;
values varied from 74 to 13595 (MFI, SA), from 0.152 to
2.305 (OD, 450 nm, ELISA) and from 0 to 51.28*105
(medTSI, PGA). Anti-A/B antibody levels were calculated as
distribution of the median and additional median absolute
deviation.
Statistical analysis
In the combination of three different immuno-assays one of
the major problems is the absence of a ‘gold’ standard
method, which means there is no experimental approach
available, which can be taken as a norm of measuring anti-
glycan antibodies. Neither has an internal standard nor a
background threshold been established , and the data values
achieved in each method are independent from each other,
which make the direct comparison impossible: (A) ELISA
values reflect the oxidized product of the chromogen TMB
(3, 3′, 5, 5′-tetramethylbenzidine) and is a substrate
conversion based on an enzymatic reaction; (B) printed
glycan array (PGA) and suspension array (SA) (R-phyco-
erythrin) results are achieved due to fluorescence measure-
ments. These differences lead to data values, which require
data mining before method comparison. When dealing with
parameters of different units and scales it is very important
to standardize or normalize data in order to allow for a
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reliable comparison. Here we used standardization of data as it
transforms datasets into a mean zero and a unit variance and
keeps ranges similar and variables different. This is also the
most commonly used method for normalization and compar-
ison of methods incorporating differing datasets. Whilst PGA
data were pre-processed [6], SA raw data were log-
transformed to improve interpretability and visualization. To
solve the problem of different data values, all data sets were
standardized as follows: z=(xi – xmean)/xsd. Standardized data
(z) were generated for each vector data set (xi) by subtraction
by their mean (xmean) and division of their standard deviation
(xsd), and called ‘standardized antibody measurements’
(SAM). Combined graphical and statistical interpretations of
method-comparison studies were performed and included
scatter plots combined with correlation and regression analysis
[30]. Data analysis, including calculation of mean, median,
standard deviation and coefficient of variation was performed
using the open source statistical programming language R
(http://CRAN.R-project.org/, version 2.8.1). Statistically sig-
nificant differences were proved for each method by the
Wilcoxon rank sum test or student t test. Concordance
correlation coefficients (rCCC) [31], which evaluate the degree
to which pairs of observations fall on the 45° line through the
origin, were calculated and compared within all independent
methods (R package epiR). Direct comparison of two
methods was performed using parametric linear regression
[32, 33]. Non-parametric testing of median signals among all
known blood groups was measured using the Kruskal-Wallis
rank sum test. For comparisons of high versus low anti-glycan
antibody levels in correlation with known blood groups,
sensitivity, specificity and area under the curve (AUC) were
calculated for each method (R package ROCR [34]). The best
cut-off between observed false negative and false positive
values was described as the “precision-recall break-even
point” [34], the point at which precision equals recall and
predictions are made due to the prevalence within the data
given. All p-values<0.05 were taken as significant.
Results
Detection of anti-A and anti-B antibodies
Using PGA, we observed higher antibody binding levels for
Btri than for Atri with higher individual variability of the
latter, consistent with the literature [6]. The same pattern
was observed in ELISA, followed by lower individual
variability of both anti-glycan antibodies, indicated by
median absolute deviation (data not shown). In contrast to
PGA and ELISA, data using SA revealed no significant
difference between general levels of anti-A and anti-B antibody
binding, accompanied by higher individual variability in anti-A
antibody binding.
Direct comparison of all three methods, based on scatter
plots and linear regression model revealed a pattern of
positive correlation, ranging from moderate to high (Fig. 1).
The observations were found to be subject (here: glycan)
independent, which was indicated by absence of difference
in both linear regression models in all three binary
comparisons. The highest Concordance Correlation Coef-
ficients (rccc) was observed between PGA and SA (Fig. 1,
with rccc 0.83 for Atri and 0.70 for Btri). These positive
correlations were displayed by the proximity of linear
regression lines to the equality line for both antigens.
Moderate correlation was observed for ELISA and SA in
Atri and Btri antigens (rccc 0.68 and 0.71, respectively,
Fig. 1), with the weakest correlation between ELISA and
PGA (rccc of 0.54 (Atri) and 0.41 (Btri)). Anti-glycan
antibody levels correlated significantly with each other
across all three methods (p<0.05). In PGA vs. SA and
ELISA vs. PGA the correlation characteristics were slightly
more pronounced for A antigen than for B antigen, which is
indicated by higher rccc values (rccc of 0.83 vs. 0.7 in PGA
vs. SA and 0.54 vs. 0.41 in ELISA vs. PGA, Fig. 1).
Discrimination between ABO blood groups
To define how various assays distinguish between blood
groups, we performed non-parametric tests for all three data
sets. All glycan-based immunoassays were able to distin-
guish between blood groups (Fig. 2). As expected, highly
significant differences (p<0.01) between the known blood
group antigens A and B were found in each applied method
(SA, ELISA and PGA). Strong discrimination of antibody
levels for Atri was observed in all three methods with the
highest detected by suspension array (SA, p<0.0001; PGA,
p=0.0004; ELISA, p=0.0004). Less significant discrimina-
tion in all three assays were found for Btri (SA, p=0.0058;
PGA, p=0.006, ELISA p=0.013). Distribution of anti-A/B
antibodies using a pool of immunoglobulin subtypes (IgG,
IgA, and IgM) were concordant with classical haemagglu-
tination data [35]. The accuracy of all applied assays to
discriminate between expected anti-glycan antibody levels
was evaluated by ROC curves. Based on Atri as a binary
classifier, data from blood groups with low anti-A antibody
levels (BG A and AB) were combined, as were the data
from BG with higher anti-A antibody levels (BG B and O).
In contrast, data from blood groups B and AB versus blood
groups A and O were combined for comparison, based on
Btri as the binary classifier. Sensitivity, specificity and Area
Under the Curve (AUC) were calculated for each assay as a
measure for discriminatory power. Hereby, SA revealed the
best discrimination between low and high anti-A antibody
levels with excellent selectiveness (sensitivity 93.3%,
specificity 93.7%, AUC 0.96; Fig. 2c). An equal sensitivity,
specificity and AUC of 0.95 was achieved for ELISA; PGA
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revealed a comparably lower sensitivity (86.7%), specificity
(87.5%) and AUC (0.93). Interestingly, the overall pattern
changed in anti-B antibody levels, and sensitivity, specificity
and AUC values decreased for all three methods (PGA, AUC
0.85; SA, AUC 0.87; ELISA, AUC 0.78, respectively)
(Fig. 2d).
Expression of ovarian cancer biomarker P1 trisaccharide
Based on the findings that anti-A and anti-B antibody
profiles represent an assay independent pattern we further
investigated one potential ovarian cancer biomarker, which
was previously identified by us using PGA in a discovery
Fig. 1 Comparison of glycan-based immunoassays using ABO blood
groups. Scatter plots demonstrating the correlation between printed
glycan array, suspension array and ELISA. The x- and y- axes represent
standardized signals for each method, the dashed line indicates linear
regression for Atri (empty dots) and dotted line for Btri (filled dots). The
solid line indicates intercept of 0 and slope of 1. Each dot is represented
by two-method measurement of one plasma sample (n=31). Rccc
represents concordance correlation coefficient per blood group including
the 95% confidence interval in brackets
Fig. 2 Binding of plasma anti-A/B antibodies to Atri and Btri. Boxplots
generated for SA (suspension array), PGA (printed glycan array) and
ELISA, demonstrate the distribution of anti-glycan antibodies to glycans
Atri (a) and Btri (b). Blood groups are shown on the x-axis, standardized
signals for each method are on the y-axis. Kruskal-Wallis p-values
indicate the equality of population medians among blood groups. ROC
curves for blood groups A and AB (low anti-A antibody levels) versus
B and O (high anti-A antibody levels) were determined by SA, PGA
and ELISA (c). Data from blood group B and AB versus blood group A
and O were combined respectively (d)
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approach; antigen P1 (Galα1-4Galβ1-4GlcNAcβ) [11]. In
order to approach this question with appropriate com-
parative numbers, we increased the cohort of 31 patients
where blood groups were known to a cohort of 48
samples, including 23 undifferentiated serous cancer
patients of ovarian, tubal and peritoneal origin, totaling
to 24 benign and 24 cancer cases (Table 1). Glycan-based
assays were plotted against each other and their relation-
ship determined by linear regression analysis. In compar-
ison to the ABO assays, anti-P1 correlations across the
three assays appeared to be much weaker. The comparison
between PGA and SA showed the highest correlation (rccc
=0.55 for the entire cohort, 0.58 for benign and 0.43 for
malignant samples, Fig. 3). The discrimination between
control and cancer patients showed the same trend in both
SA and PGA with lower anti-P1 antibody levels in the
cancer cohort (p=0.03 and p=0.004, respectively, Fig. 3).
No improvement in discrimination could be achieved in
the comparisons of PGA or SA with ELISA assay (Fig. 3).
Discussion
In the current study, which is in continuity of two previous
publications of ours using both a newly described PGA
and SA [11, 21], we investigated the efficacy and
selectivity of three custom-developed immunoassays to
profile anti-glycan antibodies in individual human plasma
samples. All three methods adequately reflected the
known serological isohaemagglutinin distribution within
ABO blood groups, with the best being SA and PGA. The
correlation between all three assays was more distinctive
for the detection of anti A-antibodies than for anti-B
antibodies. Our results indicate that anti-A/B blood group
antibodies positively correlated with each other and that
all glycan immunoassays could detect these with statistical
significance. They demonstrated method-independent ten-
dencies due to their high affinity, which reflects their
strong biological importance even in a small patient cohort
[26].
In contrast, anti-P1 correlations across the three assays
were considerably less pronounced although it was primarily
detected by PGA with the highest discriminative power in a
discovery approach in non-mucinous ovarian cancers.
Nevertheless, with equal control to cancer patient numbers
we did improve the correlation of this cancer-specific marker
for the comparison of PGA and SA.
The discrepancy between PGA and the other two glycan
immunoassays could reflect differences in the assay design,
like glycan display, density and surface presentation, as
well as the various assay conditions such as temperature,
serum dilution, static/dynamic characteristics, and antigen/
antibody ratio (Table 2). The most dramatic difference
between all three assays appears to be the antibody/antigen
ratio. There is an excess of antibodies over antigen in PGA
only, whereas in ELISA and SA the ratio of antigen/
antibody is opposite (Table 2). As a result, in these two
assays all antibodies of a particular specificity are allowed
to bind to their glycan ligands on the array. Thus, ELISA
and SA are more susceptible to promiscuous binding than
PGA, where a competition between antibodies takes place.
Additional factors, which play a role in the different
binding patterns of the three methods include: 1) temper-
ature; 2) polyethylene glycol (PEG) linking of glycans (in
PGA) reducing nonspecific binding similarly to a “stealth”
effect in PEGylated liposomes [36]; 3) flow conditions of
SA; 4) random mutual orientation of glycans in a polymeric
display (SA and ELISA) in contrast to more restricted
Fig. 3 Anti-P1 antibody levels in suspension array and printed
glycan array. Boxplots demonstrate the distribution of anti-glycan
antibodies directed to P1 in benign control (n=24; BD) and cancer
plasma samples (n=24; CA) for suspension and printed glycan
arrays as well as ELISA
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orientation of glycans in a PGA monolayer (Table 2). This
could indicate that PGA has advantages compared to the
other two glycan immunoassays; certainly it demonstrates
that each method strongly depends on the task it is used for,
taking into account the advantages as well as limitations. SA
and PGA both require a lower amount of glycans (at least
three orders of magnitude) and SA needs even lower
quantities of glycan-binding proteins. Whilst SA and ELISA
have a broader flexibility and allow assay reconfigurations,
PGA is exceptionally convenient for screening large numbers
of yet biologically unknown glycans besides demonstrating
low background and a wide dynamic range. Whilst PGA
is ideal for a discovery approach, suspension array, which
is based on glycosylated fluorescent beads [21] seems
ideal for the diagnostic analysis of human plasma anti-
bodies in a clinical setting. In biomarker discovery studies
the use of only one assay with appropriate sensitivity,
specificity and reproducibility might be sufficient if
validation is performed in a second independent patient
cohort. In contrast, crucial conclusions based on data from
one assay might not be sufficient in the case of basic
research, as each glycan could be showing physiologically
important patterns only in one of the other assays. As each
method allows a different view into the investigation and
specificity of glycan binding patterns [6, 37] or motif-
based analysis of specific glycan-binding proteins [38],
the cumulative method approach seems more preferable.
Whilst in datasets obtained with a discovery PGA
approach, ELISA and SA assays might be suggested as
validation methods, they should be considered as highly
controversial and not concordant due to essential differ-
ences in assaying conditions.
Table 2 Comparative conditions of anti-glycan immunoassays
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Glycan
G
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Glycan
fluorescent microspheresstreptavidin
biotin
37°C 37°C 20°C
static static flow
polymeric dense monomeric polymeric
~10 glycans 200-400 glycans ~10-20 glycans
1:1,000 1:15 1:40
10 fmol/mL 700 fmol/mL 250 fmol/mL
0.1 fmol 100 fmol 10 fmol
10,000 fmol per 
well***
10 fmol per spot
1,000 fmol per well
(2000 beads)
1:100,000 10:1 1:100
*According to experiments on glycan affinity isolation the range of highest rank human antibodies lies in 1–10microgram per mL interval (P. Obukhova
et al., Glycoconj J, submitted)
**Calculated for 0.1 mL well in ELISA, 1 mL working volume of sample applied onto microchip, and 50 μl of sample for SA
***[39]
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